Nearly seven decades after being given to their mothers without federal approval, the American children of the thalidomide era are pressing the U.S. government to formally acknowledge that they exist. The drug, a sedative developed in Germany and never cleared for general U.S. use, was nonetheless handed to thousands of pregnant patients in the late 1950s and early 1960s. Some of those pregnancies produced children with severely deformed limbs, and those children are now adults seeking an official reckoning with a chapter of medical history that federal records appear to understate.
The story begins in 1960, when the Cincinnati-based pharmaceutical company William S. Merrell applied to the Food and Drug Administration to market the German-made drug. The company expected a routine approval process and hoped to have the sedative on American store shelves before Christmas. That approval did not arrive in 1960, and it did not arrive in 1961 either. The delay traced to a single medical reviewer inside the agency who refused to let the drug through without more evidence.
That reviewer was Dr. Frances Oldham Kelsey, an FDA pharmacologist. Her insistence on holding the application reshaped how the agency evaluated new drugs, and is widely credited with producing the far more demanding testing and approval standards that govern the FDA today. In 1962, President John F. Kennedy publicly credited Kelsey with sparing the United States the "terrible human tragedy" that had been visited on families in Germany, where thalidomide had been sold far more widely.
But as survivors and historians point out, that account of prevention was only partly true. Even as the FDA withheld approval, American doctors were already dispensing thalidomide to thousands of patients, pregnant women among them. The children of some of those women were born with shortened, misshapen limbs. In other words, the agency stopped the drug from entering the normal marketplace, but it did not stop the drug from reaching American patients.
That gap — between a regulator's refusal to approve a product and the willingness of physicians to prescribe it anyway — sits at the center of the survivors' case. The people now seeking recognition say the nation's celebrated regulatory victory has obscured the harm that did occur, because the official narrative stops at the approval decision and does not follow the drug into exam rooms, hospitals and family histories.
"We go to doctors today who say it didn't happen here in the United States," said Gwen Riechmann, who was born with phocomelia, the shortened limb deformity that is the signature birth defect associated with thalidomide. "Oh yeah, it did," she said.
Riechmann's own account is rooted in her family's experience. When her mother was pregnant with her in the early 1960s, the treating physician gave the expectant mother a new sedative. Riechmann, who lives in Ohio, is among the most visible American advocates pressing for official acknowledgment of survivors.
Her condition, phocomelia, is rare. It is somewhat more common outside the United States, in countries such as Britain and Germany, where thalidomide was more widely sold. That pattern is part of what makes the American count contentious: a condition statistically associated with the drug overseas can be harder to find in domestic medical records if no one expected to be looking for it.
Survivors and advocates maintain that the number of thalidomide survivors living in the United States exceeds what federal authorities acknowledge. Their argument rests partly on the experience Riechmann describes — clinicians surprised to encounter a condition they associate with other countries — and partly on the absence of a single authoritative federal register of Americans exposed to the drug.
Recognition, in their view, is about more than symbolism. An official acknowledgment would establish that American children were affected alongside those in Britain, Germany and other countries, correcting a historical record that many of them say they have had to argue against one doctor at a time. It would also give shape to questions about who was given the drug, under what authority, and without what informed consent.
There is a sharp irony in the legacy Kelsey left behind. The regulations shaped by her caution are among the most robust drug-safety systems in the world, but they emerged from an era in which investigational access was far less disciplined than the rules eventually written. The thalidomide episode is often taught as a story about a regulator who said no; the survivors tell a fuller story, one that also asks how thousands of patients came to receive the drug anyway.
The recognition campaign also carries implications for how the wider medical community treats survivors today. Adults living with thalidomide-related deformities are a population with specific, ongoing healthcare needs, and for many of them the fight for documentation has been part of getting those needs taken seriously. Each disputed case of whether the drug touched an American family carries consequences beyond paperwork.
For survivors like Riechmann, the immediate demand is straightforward: a federal government that kept thalidomide off the market should also acknowledge the Americans who were exposed to it before that prohibition took hold. The historical lesson of the 1960s is well known. The question now is whether the count of those who survived it will finally match the record of what happened.
(0)